Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
2011-07-05
2011-07-05
Loewe, Sun Jae Y (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
C514S602000, C564S080000, C564S084000
Reexamination Certificate
active
07973078
ABSTRACT:
A compound that can be used as an agent for treating a disease associated with an EP1 receptor, in particular a lower urinary tract symptom. It was confirmed that a sulfonamide compound having an amide structure and characterized by a chemical structure in which a carbon atom in the amide bonds to the N atom in sulfonamide through lower alkylene, or a salt thereof, has a potent EP1 receptor antagonistic activity, accomplishing the present invention. Since the sulfonamide compound of the present invention or a pharmaceutically acceptable salt thereof has a potent EP1 receptor antagonistic activity, it is useful as an agent for treating a disease associated with an EP1 receptor, in particular, a lower urinary tract symptom.
REFERENCES:
patent: 6211197 (2001-04-01), Belley et al.
patent: 6448290 (2002-09-01), Ohuchida et al.
patent: 6790866 (2004-09-01), Nagao et al.
patent: 2001/0031766 (2001-10-01), Belley et al.
patent: 2003/0060460 (2003-03-01), Ohuchida et al.
patent: 2004/0082653 (2004-04-01), Nonaka et al.
patent: 2004/0102524 (2004-05-01), Hughes
patent: 2005/0020646 (2005-01-01), Newgreen et al.
patent: 2005/0124672 (2005-06-01), Naganawa et al.
patent: 2005/0245535 (2005-11-01), Hangeland et al.
patent: 2006/0030713 (2006-02-01), Naganawa et al.
patent: 2006/0100195 (2006-05-01), Maruyama et al.
patent: 2006/0100219 (2006-05-01), Kauffmann-Hefner et al.
patent: 1 447 096 (2004-08-01), None
patent: 1 642 594 (2006-04-01), None
patent: 2002 526517 (2002-08-01), None
patent: 2004 520433 (2004-07-01), None
patent: 2005 206492 (2005-08-01), None
patent: 97 36583 (1997-10-01), None
patent: 98 27053 (1998-06-01), None
patent: 00 26197 (2000-05-01), None
patent: 00 50391 (2000-08-01), None
patent: 00 69465 (2000-11-01), None
patent: 01 02363 (2001-01-01), None
patent: 01 12186 (2001-02-01), None
patent: 02 20463 (2002-03-01), None
patent: WO 02/32864 (2002-04-01), None
patent: 02 072145 (2002-09-01), None
patent: 02 072564 (2002-09-01), None
patent: 2004 033418 (2004-04-01), None
patent: 2005 000356 (2005-01-01), None
Coli et al, Expert Opinion Invest. Drugs, 2007, 16(7) 999-1007.
Prostatitis (2009), http://www.mayoclinic.com/health/prostatitis/DS00341/DSECTION=treatments-and-drugs.
Giannitsas et al., Expert Opin. Ther. Patents (2009) 19, 107-117.
Smith et al., caplus an 2000:608717.
Abrams, Paul et al., “The Standardisation of Terminology of Lower Urinary Tract Function: Report from the Standardisation Sub-committee of the International Continence Society”, Neurourology and Urodynamics, vol. 21, pp. 167-178, (2002).
Schuessler, B. “Comparison of the mode of action of prostaglandin E2(PGE2) and sulprostone, a PGE2-derivative, on the lower urinary tract in healthy women”, UROL RES, vol. 18, No. 5, pp. 349-352, (1990).
Ishizuka, Osamu et al., “Prostaglandin E2-Induced Bladder Hyperactivity in Normal, Conscious Rats: Involvement of Tachykinins”, The Journal of Urology, vol. 153, No. 6, pp. 2034-2038, (1995).
“Prostaglandin E2”, Journal of the Japanese Urological Association, vol. 92, No. 2, PM 304, (2001).
“Prostaglandin E2”, The 89thAnnual Meeting of the Japanese Urological Association, Kobe, PM 305, (2001).
Nakayama, Yoshito et al., “Role of Prostaglandin Receptor EP1, in the Spinal Dorsal Horn in Carrageenan-induced Inflammatory Pain”, Anesthesiology, vol. 97, No. 5, pp. 1254-1262, (2002).
Omote, Keiichi et al., “The Effects of Intrathecal Administration of an Antagonist for Prostaglandin E Receptor Subtype EP1on Mechanical and Thermal Hyperalgesia in a Rat Model of Postoperative Pain”, Anesth Analg, vol. 95, No. 6, pp. 1708-1712, (2002).
Kawahara, Hiroyasu et al., “A Prostaglandin E2Receptor Subtype EP1Receptor Antagonist (ONO-8711) Reduces Hyperalgesia, Allodynia, and C-fos Gene Expression in Rats with Chronic Nerve Constriction”, Anesth Analg, vol. 93, No. 4, pp. 1012-1017, (2001).
Sarkar, Sanchoy et al., “The Prostaglandin E2 Receptor-1 (EP-1) Mediates Acid-Induced Visceral Pain Hypersensitivity in Humans”, Gastroenterology, vol. 124, No. 1, pp. 18-25, (2003).
McKeown, Stephen C. et al., “Identification of novel glycine sulfonamide antagonists for the EP1Receptor”, Bioorganic & Medicinal Chemistry Letters, Elsevier, vol. 17, No. 6, pp. 1750-1754, (2007).
Hall, Adrian et al., “Identification and optimization of novel 1,3,4-oxadiazole EP1receptor antagonists”, Bioorganic & Medicinal Chemistry Letters, Elsevier, vol. 17, No. 16, pp. 4450-4455, (2007).
Office Action issued Aug. 20, 2010, in Chinese Application 200780029730.2 (with English-languageTranslation).
A.J. Wein et al., Urology, vol. 60 (Supplement 5A), pp. 7-12 (2002).
K.T. McVary, The American Journal of Managed Care, vol. 12(5 suppl), pp. S122-S128 (2006).
AUA Practice Guidelines Committee, The Journal of Urology, vol. 170, pp. 530-547 (2003).
Dler Besarani et al., BJU International, vol. 94(9), pp. 1245-1247 (2004).
Z. Sikafi et al., British Journal of Urology, vol. 57, pp. 308-310 (1985).
M. Wyllie, BJU International, vol. 96, pp. 909-910 (2005).
C. Lowell Parsons., Expert Opin. Pharmacother., vol. 7(4), pp. 411-419 (2006).
G. M. Habermacher et al., Annu. Rev. Med., vol. 57, pp. 195-206 (2006).
Office Action issued Jan. 7, 2011, in Indonesia Patent Application No. W-00 2009 00334 (with English-language Translation).
Extended European Search Report issued Jan. 13, 2011 in EP 07 79 2264.
Database: Beilstein [Online], Beilstein Institute for Organic Chemistry, Frankfurt-Main, DE, XP-002614372, Database Accession No. 3473782, 1950, 1 page.
Database: Beilstein [Online], Beilstein Institute for Organic Chemistry, Frankfurt-Main, DE, vol. 29, XP-002614373, Database Accession No. 2769102, 1963, p. 519.
Database: Beilstein [Online], Beilstein Institute for Organic Chemistry, Frankfurt-Main, DE, vol. 32, XP-002614374, Database Accession No. 2786699, 2773408, 1962, 2 pages.
Database: Beilstein [Online], Beilstein Institute for Organic Chemistry, Frankfurt-Main, DE, vol. 30, XP-002614375, Database Accession No. 2782596, 2676969, 2764955, 1964, 3 pages.
Database: Beilstein [Online], Beilstein Institute for Organic Chemistry, Frankfurt-Main, DE, vol. 34, XP-002614376, Database Accession No. 2767615, 1964, p. 2408.
Anna Quattropani, et al., “Discovery and Development of a New Class of Potent, Selective, Orally Active Oxytocin Receptor Antagonists”, J. Med. Chem., vol. 48, XP-002614377, 2005, pp. 7882-7905.
Database: Beilstein [Online], Beilstein Institute for Organic Chemistry, Frankfurt-Main, DE, vol. 29, XP-002614388, Database Accession No. 2817880, 1963, p. 1062.
Azami Hidenori
Fukuda Yuta
Kubota Hideki
Ono Kazuki
Toda Susumu
Astellas Pharma Inc.
Loewe Sun Jae Y
Oblon, Spivak McClelland, Maier & Neustadt, L.L.P.
LandOfFree
Sulfonamide compound or salt thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Sulfonamide compound or salt thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sulfonamide compound or salt thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2667100